With respect to the audience for the results of the scorecard, there was some debate as to whether the result should be immediately made available and shared first among the GU oncology community, including the CUA and CUOG, to allow for improvement.
During the deliberations at the 2016 Bladder Cancer Quality of Care Meeting, the participants suggested that the initiative could begin immediately, with CUOG and CUA members performing their upcoming research projects using a common name (e.g., the Canadian Bladder Cancer Network).
With respect to who would lead this initiative, the participants recommended a multi-organizational approach, with members of this working group soliciting and obtaining the endorsement of the Canadian Urologic Association (CUA), Canadian Urologic Oncology Group (CUOG), Genito-Urinary Radiation Oncologists of Canada (GUROC) and Genito-Urinary Medical Oncologists of Canada (GUMOC).
It was suggested that a letter be prepared in support of the CBCIS and the Quality of Care initiative and signed by the CUOG executive board.
This has now been explored in three randomized trials (Table 1).[sup.5]-[sup.7] The National Cancer Institute of Canada (NCIC) PR3/ Canadian Urologic Oncology Group (CUOG
)/Medical Research Council (MRC) UK PR07 study randomized 1205 patients with high-risk, locally advanced disease to treatment with combined modality therapy (RT and lifelong ADT) or treatment with ADT alone.[sup.5] With a median follow-up of 6 years, combined modality treatment resulted in a 23% reduction in overall mortality and a 46% reduction in disease-specific mortality (Fig.